One of the dangerous complications of COVID-19 is the appearance of blood clots. Heparin can reduce the likelihood of this condition. Scientists have now shown that early administration of this drug at a therapeutic dose can reduce the risk of adverse outcomes by 22%
Heparin is an anticoagulant that is regularly administered in low doses to hospitalized patients. It effectively stops blood clots and reduces inflammation. In a new study, the authors wanted to investigate the effect of taking this drug on primary outcome options, which included transferring a patient to intensive care, connecting him to a ventilator, or death.
In an open, randomized, multicenter, rapid study, the authors examined the benefits of administering a therapeutic full dose of heparin versus a prophylactic low dose in the context of thrombosis prevention in moderate COVID-19 patients. It turned out that one of the variants of the primary outcome with the introduction of a full dose of heparin was observed in 16% of patients, while at a lower dose, this proportion was 22%.
The authors found that a therapeutic dose of heparin reduced the chances of death from all causes within 28 days of administration by 78% compared to a low dose of the drug. The researchers also presented a meta-analysis that clearly showed that therapeutic doses of anticoagulant are beneficial for moderately ill hospitalized COVID-19 patients. For seriously ill patients, data on the effectiveness of heparin are not given in the article.
The researchers plan to continue assessing the effect of anticoagulants on the risk of complications from coronavirus infection. COVID-19 is known to increase the risk of blood clots, the separation of which from the walls of blood vessels often leads to death due to thromboembolism. Heparin prevents blood clots from forming, thereby reducing the likelihood of death from this condition.
A preprint of the article is presented on the MedRxiv.org website.